Background: Paclitaxel has shown significant anti-tumor activity against non-small cell lung cancer (NSCLC); however, resistance to paclitaxel frequently occurs and represents a significant clinical problem and its underlying molecular mechanism remains elusive. Methods: Long-term treatment of culture cell with paclitaxel was carried out to mimic the development of acquired drug resistance in NSCLC. Cell proliferation and clonogenic assay and apoptosis evaluation were carried out to determine the efficacy of paclitaxel on NSCLC cells. Western blot analyses were performed to determine the expression and activation of proteins. Apoptosis enzyme-linked immunosorbent assay was used to quantify cytoplasmic histone-associated DNA fragments. Microarray analyses were applied to explore both mRNA and miRNA expression profiles in NSCLC cells followed by integrative analysis. qRT-PCR was carried out to verify the differentially expressed mRNAs and miRNAs. Results: The expression of 652 genes was shown to be changed at least 2-fold in paclitaxelresistant NSCLC (H460_TaxR) cells with 511 upregulated and 141 downregulated as compared with that in parental H460 cells. The differentially expressed genes were functionally enriched in regulating the cell proliferation, cell death, and response to endogenous stimulus, and clustered in pathways such as cancer and signaling by the G protein-coupled receptor (GPCR). Moreover, 43 miRNAs were shown to be differentially expressed in H460_TaxR cells with 15 upregulated and 28 downregulated as compared with parental H460 cells. A total of 289 pairs of miRNA-potential target gene were revealed in H460_TaxR cells by bioinformatics analysis. Furthermore, integrative analysis of miRNAs and gene expression profiles revealed that dysregulated miR-362-3p, miR-766-3p, and miR-6507-3p might confer paclitaxel resistance in NSCLC via targeting MAPT simultaneously. Conclusion: Our findings suggested that specific manipulation of MAPT-targeting miRNAs may be a novel strategy to overcome paclitaxel resistance in patients with NSCLC especially large-cell lung carcinoma.
Introduction
Lung cancer remains the most commonly diagnosed cancer and the leading cause of cancer-related deaths, with 2.1 million new cases and 1.8 million deaths in 2018 worldwide. 1, 2 Of all pathological types, non-small cell lung cancer (NSCLC) accounts for approximate 85% of all lung cancers and more than 65% of the patients with NSCLC present with locally advanced or metastatic disease. 3, 4 The major treatment options for patients with NSCLC are determined on the basis of histologic features and staging according to the eighth edition of the TNM (T, N, and M represent tumor, lymph node, and metastasis, respectively) classification for lung cancer. 5 Generally, the current treatment for lung cancer patients who have been diagnosed at an early stage is surgical resection followed by chemotherapy; however, majority of the patients will eventually experience disease progression and require further treatment. 6, 7 Paclitaxel, either as single agent or combined with other therapeutics, has shown significant anti-NSCLC activity. [8] [9] [10] In advanced stages of NSCLC, the efficacy of paclitaxel in combination with a platinum compound has also been confirmed by a meta-analysis of 16 randomized trials. 11 However, either intrinsic or acquired resistance to paclitaxel frequently occurs and represents a significant clinical problem. 12 We had previously shown that microRNA-mediated epigenetic targeting of survivin significantly enhances the antitumor activity of paclitaxel against NSCLC. 13 In the current report, we investigated both the gene and miRNAs expression profiles in paclitaxel-resistant large-cell lung carcinoma cells, a pathological type of relative small population of NSCLC. An integrative analysis of miRNAs and gene expression profiles was also carried out.
Materials and methods

Reagents and antibodies
Paclitaxel was obtained from the 900th Hospital of the Joint Logistics Team pharmacy (the Former Fuzhou General Hospital). The CellTiter96 AQ cell proliferation kit (Cat.#G3582) was a product of Promega (Madison, WI, USA). Oligonucleotides were synthesized in Sangon (Shanghai, China). Antibodies against PARP (Cat.#9542) and Caspase-3 (Cat.#9665) were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA); antibody against β-actin (Cat.#A5441) was the product of Sigma (St. Louis, MO, USA).
Cells and cell culture
Human large-cell lung carcinoma cell line H460 was obtained from American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS). All cells were cultured in a 37ºC humidified atmosphere containing 95% air and 5% CO 2 and were split twice a week.
To mimic the development of acquired paclitaxel resistance in vitro, parental H460 cells were maintained in culture medium with low dose of paclitaxel started from 1 nmol/L initially. Cells were then split twice a week and maintained in culture medium with gradually increased dose of paclitaxel every 2 weeks. After 6 months, paclitaxel-resistance NSCLC cells developed from H460 were maintained in culture medium with 40 nmol/L of paclitaxel for normal culture.
Cell viability assay
The CellTiter96 AQ cell proliferation kit (Cat.#G3582, Promega) was used to determine cell viability as previously described. 13 Briefly, cells were plated onto 96-well plates for 24 hrs, and then grown in either RPMI1640 medium with 0.5% FBS as control or the same medium containing different concentrations of paclitaxel, and then incubated for another 72 hrs. During this period, the medium was refreshed daily maintaining the same treatment. After reading all wells at 490 nm with a microplate reader, the percentages of surviving cells from each group relative to controls, defined as 100% survival, were determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS).
Clonogenic assay
The parental and paclitaxel-resistant human SCLC cancer cells H460 were plated onto 6-well plates and incubated at 37°C with 5% CO 2 . After 24 hrs, the culture medium was replaced daily with 2 mL fresh medium containing 0.5% FBS or the same medium containing indicated concentrations of paclitaxel for long-term incubation. After 2 weeks, cells were stained with 0.5% crystal violet (dissolved in 25% methanol) and clone number was quantified with QuantiOne software of Fluor-S TM Multimager (Bio-Rad Laboratories, Inc., Hercules, CA) at the end of the experiments.
Western blotting analysis and quantification of apoptosis
Protein expression and activation were determined by Western blotting analysis as previously described. 14 5ʹ-AAGATCGGCTCCACTGAGAA-3; reverse primer: 5ʹ-ATGAGCCACACTTGGAGGTC-3ʹ), qRT-PCR was performed using the FastStart Universal SYBR Green Master Mixes (Roche) by a 7900HT Fast Real-Time PCR system (Applied Biosystems) as we had described previously. 15 The expression of β-actin was used as an internal control (forward primer: 5ʹ-AGAGCTACGA GCTGCCTGAC-3; reverse primer: 5ʹ-AGCACTGTG TTGGCGTACAG-3ʹ). The expression of mature miR-362-3p, miR-766-3p, miR-6507-3p, and RNU6B was measured by qRT-PCR using TaqMan Assays (Applied Biosystems) as described previously. 15 The relative mRNA and miRNA levels were calculated using the comparative Ct method (2 −ΔΔCt ).
Statistical analysis
All results were confirmed by at least three independent experiments. Data are presented as mean±SD. Student's ttest or one-way ANOVA was carried out to analyze the differences between two groups or multiple groups. Values of P<0.05 were considered significant.
Results
Establishment of paclitaxel-resistant NSCLC cells
To establish a stable NSCLC cell subline with significant resistance to paclitaxel, parental H460 cells were subjected to growth in culture medium with gradually increased dose of paclitaxel persistently to mimic the development of acquired drug resistance in vitro. Six months later, NSCLC cell subline with significant resistance to paclitaxel was developed from parental H460 without obvious morphology change (data not shown). The subline was nominated as H460_TaxR. As shown in Figure 1A , Figure 1D and E).
Collectively, our results demonstrated that an NSCLC cell subline H460_TaxR with significant resistance to paclitaxel was established successfully. (Figure 2 , P<0.05). Of these genes, the top 10 genes that were most significantly up-or downregulated in H460_TaxR cells are shown in Table 1 . Gene Ontology (GO, http://www.geneontology.org) function enrichment analysis based on our own microarray data showed that the differentially expressed genes in H460_TaxR cells mainly involved in regulating the cell proliferation, cell death, and response to endogenous stimulus. (Table 2 ). Meanwhile, Gene Set Enrichment Analysis (GSEA) revealed that those differentially expressed genes were clustered in pathways such as cancer, 16 signaling by GPCR, cytokine and cytokine receptor interaction, and so on (Table 3) .
MiRNAs expression profile in paclitaxelresistant NSCLC cells
MiRNA has emerged as an important regulator in chemoresistance. 17 Thus, microarray analysis was also carried out to investigate the miRNAs expression profile in H460_TaxR cells with significant resistance to paclitaxel in our study. As shown in Figure 3 and Figure 4A ), we then focused our integrative analysis on candidate miRNAs targeting MAPT mRNA. Of all 28 downregulated miRNAs in H460_TaxR cells, 3 of them including miR-362-3p, miR-766-3p, and miR-6507-3p whose expression was verified by qRT-PCR were predicted to target MAPT mRNA via searching in miRDB (http://www.mirdb.org) with at least one binding site in its 3ʹ-UTR ( Figure 4B and C). Meanwhile, miR-362-3p and miR-766-3p were also predicted to target MAPT mRNA by TargetScan (http://www.targetscan.org). Furthermore, a MAPT-subnetwork was constructed via searching in STRING database (http://string-db.org) in combination with analysis of potential targets of miR-362-3p, miR-766-3p, and miR-6507-3p. As shown in Figure 4D , 13 of 14 potential targets of miR-362-3p, miR-766-3p, and miR-6507-3p were upregulated in H460_TaxR cells (Table 5) and could form a MAPT-subnetwork with protein-protein interactions. Taken together, our integrative analysis of miRNAs and gene expression profiles revealed that dysregulated a couple of microRNAs might confer paclitaxel resistance in NSCLC especially large-cell lung carcinoma via targeting MAPT simultaneously.
Discussion
Paclitaxel, initially derived from the bark of the Pacific yew tree, has long been used to treat NSCLC either as single-agent or combined with other therapeutics. hsa-miR-501-5p hsa-miR-718 hsa-miR-564 hsa-miR-630 hsa-miR-642a-3p hsa-miR-1290 hsa-miR-2392 hsa-miR-4745-5p hsa-miR-3663-3p hsa-miR-937-5p hsa-miR-4327 hsa-miR-4281 hsa-miR-1181 hsa-miR-4271 hsa-miR-371a-5p hsa-miR-5100 hsa-miR-4286 hsa-miR-6085 hsa-miR-6165 hsa-miR-1260a hsa-miR-1260b hsa-miR-106b-5p hsa-miR-19a-3p hsa-miR-590-5p hsa-miR-487b hsa-miR-4252 hsa-miR-6507-3p hsa-miR-4310 hsa-miR-634 hsa-miR-16-2-3p hsa-miR-629-5p hsa-miR-223-3p hsa-miR-98-3p hsa-miR-766-3p hsa-miR-1539 hsa-miR-4436b-5p hsa-miR-101-3p hsa-miR-301a-3p hsa-miR-129-2-3p hsa-miR-4323 hsa-miR-3180-5p hsa-miR-193a-3p hsa-miR-362-3p Treatment with paclitaxel disables spindle division and causes cell cycle arrest in phase G1/G2 of mitosis as well as induces apoptosis. 20 However, resistance to paclitaxel remains one of the main causes of treatment failure in NSCLC. 12 It is of particular significance to elucidate the underlying mechanism of paclitaxel resistance and identify new strategy to abrogate it. Mechanisms of the resistance to paclitaxel are complex as indicated by cumulative studies, which include alterations in microtubule dynamics, altered expression of β-tubulin isotypes, and also deregulated signaling pathways. [21] [22] [23] [24] In our own serial studies, we have demonstrated that activation of PI-3K/Akt signaling plays a critical role in ErbB2/ErbB3-mediated therapeutic resistance to paclitaxel mainly via upregulation of survivin. 14, 25 In addition, we have also found that microRNA-mediated epigenetic targeting of survivin significantly enhances the antitumor activity of paclitaxel against NSCLC. 12 Unexpectedly, as we did not observe the change of survivin in our established paclitaxel-resistant NSCLC cells (data not shown), an integrative gene expression profiling was applied to explore the possible novel underlying molecular mechanism of paclitaxel-resistance in NSCLC in our current study. We showed that a total of 43 miRNAs and 652 protein-encoding genes, functionally enriched in regulating the fundamental biological processes including cell proliferation and clustered in pathways such as cancer, are differentially expressed in paclitaxel-resistant NSCLC cells, which suggest that the mechanism of resistance to paclitaxel is more complicated than we had ever recognized. Upon binding to a pocket in beta-tubulin, paclitaxel inhibits the microtubule depolymerization process and interferes the progression of normal cell cycle. 19 MAPT, being a microtubule-associated protein which promotes the assembly of tubulin into microtubules to stabilize microtubule structure, 26 has been shown to compete with paclitaxel via sharing the same site. 27 As anticipated, a large body of studies had indicated that MAPT plays an important role in mediating the sensitivity of paclitaxel in several types of tumor. 18, 19, [28] [29] [30] Consistently, we also found that the mRNA expression of MAPT was significantly upregulated in paclitaxel-resistant NSCLC cells. However, the underlying mechanism of deregulated expression of MAPT remains largely unknown currently. A study by Wu and colleagues showed that miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel via regulating MAPT. 31 Recently, miR-186 was also showed to regulate paclitaxel sensitivity of NSCLC via targeting MAPT. 32 Interestingly, although both aforementioned two miRNAs remain unchanged in our established paclitaxel-resistant NSCLC cells, our integrative analysis of miRNAs and gene expression profiles revealed that deregulated miR-362-3p, miR-766-3p, and miR-6507-3p and their 13 potential targets could form a MAPT-subnetwork with protein-protein interactions and confer paclitaxel resistance in NSCLC ( Figure 4D ). Currently, since the molecular mechanism underlying deregulated miR-362-3p, miR-766-3p, and miR-6507-3p remains largely unclear, it would be of great interest to unveil it. Besides, whether there exists a causal relationship between specific silence of triple microRNAs (miR-362-3p, miR-766-3p, and miR-6507-3p) and upregulation of MAPT awaits further investigation. Taken together, our findings shed new light on the mechanism of paclitaxel resistance in NSCLC especially large-cell lung carcinoma and suggested that specific manipulation of MAPT-targeting miRNAs may be a novel strategy to overcome paclitaxel resistance in patients with NSCLC in the future.
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